Isleworth Healthcare Acquisition Corporation Warrant
ISLEW
ISLEW was delisted on the 26th of August, 2022.
0 hedge funds and large institutions have $0 invested in Isleworth Healthcare Acquisition Corporation Warrant in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 46 closing their positions.
100% less funds holding
Funds holding: 46 → 0 (-46)
100% less capital invested
Capital invested by funds: $6.08M → $0 (-$6.08M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 46
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$2.99M |
| 2 |
AC
Athos Capital
Hong Kong
|
-$1.68M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$936K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$300K |
| 5 |
BL
Bleichroeder LP
New York
|
-$17K |
ISLEW Hedge Fund Activity: Q3 2022 in Review
0 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Isleworth Healthcare Acquisition Corporation Warrant (ISLEW) for Q3 2022, worth a combined $0 — down 100% from $6.08M a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of ISLEW and 0 opened new positions — a net loss of 46 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $2.99M sold.
- 0 institutional investors held Isleworth Healthcare Acquisition Corporation Warrant (ISLEW) as of Q3 2022, down from 46 in Q2 2022.
- Funds reported $0 of Isleworth Healthcare Acquisition Corporation Warrant stock for Q3 2022, down 100% quarter-over-quarter.
- 0 funds opened new Isleworth Healthcare Acquisition Corporation Warrant positions in Q3 2022 and 46 closed out, a net change of -46 holders.
- The largest Isleworth Healthcare Acquisition Corporation Warrant seller in Q3 2022 was Radcliffe Capital Management, an estimated $2.99M sold.
Based on aggregated 13F filings for Q3 2022.